Limits...
Evaluation of Pre-Treatment Serum Levels of IL-7 and GM-CSF in Colorectal Cancer Patients.

Taghipour Fard Ardekani M, Malekzadeh M, Hosseini SV, Bordbar E, Doroudchi M, Ghaderi A - Int J Mol Cell Med (2014)

Bottom Line: We found an increase of the level of IL-7 in four patients presenting moderate stages of tumor concomitant with a decrease of the level of GM-CSF.It can be concluded that the increase of the level of GM-CSF is accompanied by CRC progression in Iranian patients.Potential therapeutic effect of IL-7 in this disease, however, needs further investigations.

View Article: PubMed Central - PubMed

Affiliation: Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

ABSTRACT
Survival of Colorectal cancer (CRC) patients is considerably stage-dependent; therefore, early diagnosis is a pivotal factor in decreasing mortality and morbidity associated with this cancer. GM-CSF and IL-7 are reported to increase in different cancers and we aimed to investigate the pre-treatment serum levels of GM-CSF and IL-7 in Iranian patients with colorectal cancer. 127 patients (68 males and 59 females) entered this study before receiving chemotherapy or radiotherapy. A control group of 50 healthy age/sex matched individuals (27 males and 23 females) were included in the study. The serum levels of GM-CSF and IL-7 were measured using commercial enzyme linked immunosorbent assays. A significantly higher level of GM-CSF was found in the sera of patients with colorectal cancer compared to healthy age/sex matched controls (P=0.013). However, there was no significant difference between the levels of IL-7 in sera of patients and controls. We observed a significant elevation in the level of GM-CSF in poorly differentiated tumors (P=0.024). Also a significant correlation between lymphatic invasion and the level of GM-CSF in sera of CRC patients was detected (P=0.01). We found an increase of the level of IL-7 in four patients presenting moderate stages of tumor concomitant with a decrease of the level of GM-CSF. It can be concluded that the increase of the level of GM-CSF is accompanied by CRC progression in Iranian patients. Potential therapeutic effect of IL-7 in this disease, however, needs further investigations.

No MeSH data available.


Related in: MedlinePlus

The comparison of the IL-7 and GM-CSF levels between patients and controls. The median values are shown by black lines in the graphics
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3927386&req=5

Figure 1: The comparison of the IL-7 and GM-CSF levels between patients and controls. The median values are shown by black lines in the graphics

Mentions: A significantly higher level of GM-CSF (12.49±27.28 pg/ml) was found in the sera of patients with colorectal cancer compared with healthy age/sex matched controls (2.21 ± 15.68 pg/ml), (P= 0.013). Due to the high variance of data the analysis was performed by non-parametric comparison of the means (Mann-Whitney) and the results were confirmed (P=0.000). However, there was no significant difference between the level of IL-7 in sera of patients (0.16 ± 1.38 pg/ml) and healthy controls (0.06 ± 0.16 pg/ml) which was also confirmed by the non-parametric statistical evaluation (P=0.088). A high percentage of CRC patients (73 out of 124, 59%) had some level of GM-CSF in their sera while only one out of 50 (2%) healthy controls were found positive for GM-CSF (Roc curve cut off point= 5.04 pg/ml). Conversely, a higher number of healthy controls (7 out of 50, 14%, figure 1) had some level of IL-7 in their sera compared to the CRC patients (4 out of 124, 3.23%, figure 1).


Evaluation of Pre-Treatment Serum Levels of IL-7 and GM-CSF in Colorectal Cancer Patients.

Taghipour Fard Ardekani M, Malekzadeh M, Hosseini SV, Bordbar E, Doroudchi M, Ghaderi A - Int J Mol Cell Med (2014)

The comparison of the IL-7 and GM-CSF levels between patients and controls. The median values are shown by black lines in the graphics
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3927386&req=5

Figure 1: The comparison of the IL-7 and GM-CSF levels between patients and controls. The median values are shown by black lines in the graphics
Mentions: A significantly higher level of GM-CSF (12.49±27.28 pg/ml) was found in the sera of patients with colorectal cancer compared with healthy age/sex matched controls (2.21 ± 15.68 pg/ml), (P= 0.013). Due to the high variance of data the analysis was performed by non-parametric comparison of the means (Mann-Whitney) and the results were confirmed (P=0.000). However, there was no significant difference between the level of IL-7 in sera of patients (0.16 ± 1.38 pg/ml) and healthy controls (0.06 ± 0.16 pg/ml) which was also confirmed by the non-parametric statistical evaluation (P=0.088). A high percentage of CRC patients (73 out of 124, 59%) had some level of GM-CSF in their sera while only one out of 50 (2%) healthy controls were found positive for GM-CSF (Roc curve cut off point= 5.04 pg/ml). Conversely, a higher number of healthy controls (7 out of 50, 14%, figure 1) had some level of IL-7 in their sera compared to the CRC patients (4 out of 124, 3.23%, figure 1).

Bottom Line: We found an increase of the level of IL-7 in four patients presenting moderate stages of tumor concomitant with a decrease of the level of GM-CSF.It can be concluded that the increase of the level of GM-CSF is accompanied by CRC progression in Iranian patients.Potential therapeutic effect of IL-7 in this disease, however, needs further investigations.

View Article: PubMed Central - PubMed

Affiliation: Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

ABSTRACT
Survival of Colorectal cancer (CRC) patients is considerably stage-dependent; therefore, early diagnosis is a pivotal factor in decreasing mortality and morbidity associated with this cancer. GM-CSF and IL-7 are reported to increase in different cancers and we aimed to investigate the pre-treatment serum levels of GM-CSF and IL-7 in Iranian patients with colorectal cancer. 127 patients (68 males and 59 females) entered this study before receiving chemotherapy or radiotherapy. A control group of 50 healthy age/sex matched individuals (27 males and 23 females) were included in the study. The serum levels of GM-CSF and IL-7 were measured using commercial enzyme linked immunosorbent assays. A significantly higher level of GM-CSF was found in the sera of patients with colorectal cancer compared to healthy age/sex matched controls (P=0.013). However, there was no significant difference between the levels of IL-7 in sera of patients and controls. We observed a significant elevation in the level of GM-CSF in poorly differentiated tumors (P=0.024). Also a significant correlation between lymphatic invasion and the level of GM-CSF in sera of CRC patients was detected (P=0.01). We found an increase of the level of IL-7 in four patients presenting moderate stages of tumor concomitant with a decrease of the level of GM-CSF. It can be concluded that the increase of the level of GM-CSF is accompanied by CRC progression in Iranian patients. Potential therapeutic effect of IL-7 in this disease, however, needs further investigations.

No MeSH data available.


Related in: MedlinePlus